GSK PLC

GSK

Equity

ISIN null / Valor 120042705

New York Stock Exchange, Inc (2025-11-21)

USD 47.19+2.34%

GSK PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

GSK PLC is a global healthcare company specializing in pharmaceuticals and vaccines, dedicated to preventing and treating a wide range of diseases. The company operates through key therapeutic areas including respiratory, immunology and inflammation, oncology, as well as HIV and other infectious diseases. Notably, GSK majority-owns ViiV Healthcare, the sole company exclusively focused on HIV treatment and prevention, aiming to end the HIV epidemic. With a robust portfolio of over 20 marketed vaccines, GSK delivers more than one million vaccine doses daily, addressing infectious diseases across all age groups. The company's approach emphasizes early intervention and the use of advanced technologies to support healthcare systems and improve patient outcomes. GSK's commitment to responsible business practices underpins its strategy for long-term growth and trust-building with stakeholders.

Summarized from source with an LLMView SourceSector: Healthcare

Total Sales Growth

In Q2 2025, GSK PLC reported total sales of £8.0 billion, representing a 1% increase at actual exchange rates (AER) and a 6% increase at constant exchange rates (CER). Specialty Medicines sales surged by 15% to £3.3 billion, while Vaccines sales grew by 9% to £2.1 billion.

Operating Profit and EPS Increase

The company saw a 33% increase in total operating profit and a 35% rise in earnings per share (EPS), primarily driven by lower CCL charges and improved profitability in key segments. Core operating profit also grew by 12%, with core EPS increasing by 15%, reflecting strong performance in Specialty Medicines and Vaccines.

Strong Performance in Specialty Medicines

Specialty Medicines were the main contributors to growth, with significant increases in Respiratory, Immunology & Inflammation (+10%), Oncology (+42%), and HIV sales (+12%). Notably, Oncology sales reached £0.5 billion, showcasing a robust 42% growth.

Cash Generation and Free Cash Flow

GSK PLC generated £2.4 billion from operations in Q2 2025, with a free cash flow of £1.1 billion. This strong cash flow supports ongoing investments in the R&D pipeline and shareholder return initiatives.

Shareholder Returns and Dividend

The company declared a dividend of 16p per share for Q2 2025 and expects a full-year dividend of 64p. Additionally, GSK has spent £822 million in the first half of 2025 as part of its £2 billion share buyback programme, underscoring its commitment to returning value to shareholders.

Guidance and Future Outlook

GSK PLC remains confident in achieving the top end of its 2025 financial guidance, projecting turnover growth of 3% to 5%, core operating profit growth of 6% to 8%, and core EPS growth of 6% to 8% at constant exchange rates. The company continues to invest in its pipeline, with several key product approvals and developments expected to drive future growth.

Summarized from source with an LLMView Source

Key figures

40.0%1Y

41.1%3Y

1.95%5Y

Performance

107%1Y

63.8%3Y

51.5%5Y

Volatility